Effects of long-acting somatostain analogue (SMS 201-995) on plasma corticotropin (ACTH) and corticotropin-releasing hormone (CRH) levels were studied in a patient (63-year-old woman) with ectopic ACTH-producing tumors associated with type I multiple endocrine neoplasia (MEN-I). The patient had undergone bilateral adrenalectomy.
Plasma CRH, as well as plasma ACTH, beta-endorphin and alpha-MSH, increased.
The hormone levels were dramatically decreased by acute administration of SMS 201-995.
Moderately higher doses of dexamethasone (0.05 or 0.1mg/kg a day) did not decrease plasma CRH or ACTH. An extremely high dose of dexamethasone (0.2mg/kg a day), however, decreased plasma ACTH, but failed to decrease plasma CRH.
Acute administration of SMS 201-995 further lowered the level of plasma ACTH even in this condition.
In addition to the decrease inACTH, SMS 201-995 decreased plasma CRH. Chronic administration of SMS 201-995 continuously decreased plasma CRH, ACTH and beta-endorphin. The decrease in these hormone concentrations accompanied the disappearance of hyperpigmentation.
These results suggested that SMS 201-995 inhibits hypersecretion not only of ACTH but also of CRH, and that the agent is therapeutically useful in normalizing the hypersecretion of these hormones.
Somatostatin
(SRIF) or long-acting SRIF analogue has been reported to be effective in suppressing the secretion of pituitary hormones, such as growth hormone (GH) in patients with acromegaly (Yen et al., 1974 , Plewe et al., 1984 , Kelijman et al., 1988 , thyrotropin (TSH) in patients with TSH-secreting pituitary tumors (Comi et al., 1987 , WemeauTet al., 1988 and corticotropin (ACTH) in patients with Nelson's syndrome (Tyrell et al., 1975 , Benker et al., 1976 , Lamberts et al., 1989 or with ectopic ACTH secretion (Bertagna et al., 1989) . However, it is not certain whether the agent is effective in inhibiting the release of hypothalamic releasing factors, such as GH-releasing hormone (GH-RH), TSH-releasing hormone (TRH) and ACTHreleasing hormone (CRH) (Lamberts, 1988) . We examined a patient with multiple endocrine neoplasia type I (MEN-I), who had ectopic (metastatic) ACTHproducing tumors with a high level of plasma CRH. In order to inhibit the hypersecretion of ACTH, SMS 201-995 was administered.
During the administration, plasma ACTH and CRH levels were monitored, and we obtained results which suggested that the agent could suppress the secretion not only of ACTH but also of CRH. In this report, we present the case and discuss the mechanism of SRIF inhibition of ACTH and CRH release in this patient.
Materials and Methods and Measurement of Hormones
The serum levels of gastrin, insulin, calcitonin, prolactin (PRL), 3, 5, 3'-triiodo-L-thyronine (T3), L-thyroxine (T4), thyroid stimulating hormone (TSH) (Daiichi Radioisotope, Inc., Tokyo, Japan), growth hormone (GH) (Dainabot Inc., Tokyo, Japan), and parathyroid hormone (PTH) (Yamasa Shouyu Co., Ltd., Tokyo, Japan) were measured by RIAs with commercially available kits as previously described (Hiramatsu et al., 1983) . Vasoactive intestinal peptide (VIP), pancreatic polypeptide (PP) (Mayo Medical Laboratory Co., New York, U. S. A.), insulin-like growth factor I (IGF-I) (Eiken Immunochemical Co., Tokyo, Japan) were also measured by RIAs with commercially available kits. Plasma levels of beta-endorphih, SRIF, glucagon (Special Reference Laboratory Inc., Tokyo, Japan), and alpha-MSH (Dainabot Inc.) were measured by RIAs with commercially available kits. Plasma ACTH was also measured by RIA with a commercially available kit (Diagnostic products Co., Los Angels, U. S. A). tration, but the plasma CRH concentration was not affected by the administration. In this condition, SMS-201-995 was also administered subcutaneously and further decreased plasma ACTH and beta-endorphin. In addition, plasma CRH was also decresed by the administration (Fig. 1) .
Examinations with computed tomography (CT) revealed the presence of multiple metastatic tumors in liver (Fig. 2) but did not disclose any enlargment of the pituitary gland. Cytology of the specimens obtained from metastatic tumors in liver revealed the presence of malignant cells derived from a pancreatic islets. In order to evaluate the function of the tumor cells, immunoreactivity to and-ACTH, anti-beta-MSH, anti-beta-endorphin and and-CRH antibodies was examined. ACTH, beta-MSH and beta-endorphin were recognized in the metastatic tumor cells (Fig. 3) hormone levels in plasma, a decrease in plasma CRH was observed (Fig. 5) . During the treatment with SMS 201-995 for 70 days, pigmentation of the lips and tongue disappeared.
Discussion
It is well documented that plasma ACTH levels are high in patients with Nelson's syndrome (Bondy, 1986 ). We could not define whether the patient presented in this report had Nelson's syndrome or not. Since the patient had undergone bilateral adrenalectomy, overproduction of ACTH and beta-endorphin in the pituitary might occur even though the pituitary tumor was not revealed in CT scanning. However, evidence of the presence of immunoreactivities against ACTH and its related peptides in tumor cells strongly suggested that the high level of plasma ACTH was caused by ectopic (metastatic) tumors in the liver. The plasma CRH concentration is also known to be increased in certain patients with Nelson's syndrome (Suda et al., 1985) . Since we do not know the CRH level before adrenalectomy in this patient, it was impossible to define whether the high level of CRH was induced by adrenalectomy or was due to hypersecretion which was associated with MEN-I (Lips et al., 1984 , Yamaguchi et al., 1980 . In either case, the high levels of plasma ACTH and CRH after adrenalectomy suggested that the patient was in a state similar to that in Nelson's syndrome.
The molar ratio of ACTH to beta endorphin in this patient was 0.16 (mean of four different simultaneous measurements), which was significantly lower than that observed in normal subjects (Table  1) . The reason why the molar ratio decreased in this patient was not clear.
It has been reported that the increased secretion of ACTH from the pituitary is able to be inhibited by the administration of SRIF or its long-acting analogue in Nelson's syndrome (Tyrrell et al., 1975 , Benker et al., 1976 , Lamberts et al., 1989 , Reichlin, 1983 . However, it was uncertain whether SRIF inhibits secretion of CRH or not.
We observed that a decrease in plasma ACTH was associated with a decrease in plasma CRH in both studies with acute and chronic administration of SMS 201-995. These results suggested that SMS 201-995 inhibited secretion not only of ACTH but also of CRH. In addition to these observations, dexamethasone-unsuppressible secretion of CRH was inhibited by the agent, which accompanied a further decrease in plasma ACTH. The results suggested that the SMS 201-995-induced decrease in plasma ACTH might be partly dependent on the agent-induced inhibition of the overproduction of CRH.
Immunocytochemical studies showed the presence of ACTH, beta-endorphin and beta-MSH in the metastatic tumor cells, suggesting that the precursor molecule of ACTH, which is known as proopiomelanocortin (POMC), had been synthesized in the tumor cells (Krieger, 1983) . CRH is known to stimulate the synthesis of POMC in pituitary cells (Vale et al., 1981) . We observed a parallel decrease in plasma CRH and these peptides during the administration of SMS 201-995.
The results indicated that the SMS 201-995-induced decrease in plasm ACTH was not only caused by direct inhibition of ACTH release but also resulted from the inhibition of CRH-induced production of POMC in the tumor cells. However, further studies, such as in vitro experiments on peptide secretion from tumor cells, and measurement of the bioactivity of plasma CRH will be required to clarify the mechanism of SMS 201-995 inhibition of the secretion of these peptides.
As mentioned above, we postulated that overproduction of CRH plays an important role in the stimulation of hypersecretion of Vol. 37, No. 6 SRIF  INHIBITS  CRH  RELEASE  IN MEN  TYPE  I ACTH from tumor cells in this case. The site of CRH secretion, however, could not be identified. We had supposed that the metastatic tumors were sites of CRH production. However, we failed to observe a positive reaction with anti-CRH antibody in immunocytochemical studies on the metastatic tumor cells. The result indicated that the excess CRH produced was held in cells other than the tumor cells, as is observed in patients with Nelson's syndrome (Bondy, 1986) .
In this study, we reported that the longacting SRIF analogue ) is effective in inhibiting CRH and ACTH secretions in a patient with ectopic ACTHproducing tumor associated with MEN-I. Although long-term administration will be required to evaluate the clinical usefulness of the agent (Bertagna et al., 1989 , Lamberts et al., 1987 , Barken et al., 1988 , we observed the disappearancce of pigmentation following administration of the agent for 70 days, suggesting that this agent may be useful in treating hypersecretion of ACTH and CRH.
